Dataset from A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00006878
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to evaluate the efficacy of intranasal esketamine 84 milligram
(mg) compared with intranasal placebo in addition to comprehensive standard of care in
reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in
participants who are assessed to be at imminent risk for suicide, as measured by the change
from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24
hours post first dose.
创建时间：
2025-02-27
